BMC Gastroenterology最新文献

{"title":"The effect of chewing gum on postoperative ileus after laparotomy for gastroduodenal perforations: a randomized controlled trial.","authors":"Joshua Muhumuza, Selamo F Molen, Godefroy N Bassara, Musa A Waziri, Stephen M Kithinji, Kiyaka M Sonye, Mugisho M Leocadie, ByaMungu P Kagenderezo, Esperant T Tshimanga, Tatana M Faustin, Herman Lule","doi":"10.1186/s12876-025-04016-5","DOIUrl":"10.1186/s12876-025-04016-5","url":null,"abstract":"<p><strong>Background: </strong>Prolonged postoperative ileus is linked to a higher risk of additional complications, longer hospital stays, and higher healthcare expenses. There are few randomized controlled trials on the impact of chewing gum on the duration of ileus in patients undergoing emergency surgery, notably those with peritonitis. Compelling evidence from studies on elective procedures demonstrates that chewing gum can lessen the duration of ileus. This trial aimed to examine the effect of chewing gum on the length of the postoperative ileus which develop after laparotomy for gastroduodenal perforations.</p><p><strong>Materials and methods: </strong>Multicentre randomized controlled trial. Fifty-two patients were randomly assigned to two treatment groups. Group A received routine care with chewing gum, while group B only received routine care. The primary outcome was the length of postoperative ileus, while the secondary outcomes were the length of hospital stay, in-hospital morbidity, and mortality. The continuous variables were compared using the nonparametric Wilcoxon Rank sum (Mann-Whitney U) test while the categorical outcomes were compared using the chi-squared test in SPSS version 26. The protocol was retrospectively registered with the WHO Pan African Clinical Trial Registry (Number: PACTR202206468032528) on the 1st of June 2022.</p><p><strong>Results: </strong>Of the 52 participants included in the analysis, the majority were males (80.8%) with a mean age of 34.23 (SD = 11.52) years. There was no statistically significant difference in the baseline characteristics of the study participants between the two groups (P > 0.05 for all). The median duration of postoperative ileus was 21.5 h less in the chewing gum group (28.5 versus 50.0, P = 0.002), while the length of hospital stay was 2.5 days less in the chewing gum group (5.4 versus 7.9, P = 0.007). There was no significant difference noted in the occurrence of complications.</p><p><strong>Conclusion: </strong>Chewing gum that is readily available and reasonably priced may help shorten the duration of post-operative ileus, which has the extra benefit of enabling early discharge.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"402"},"PeriodicalIF":2.5,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12102907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy of retrograde and antegrade enemas in the management of low anterior resection syndrome in patients undergoing rectal resection: a systematic review and meta-analysis.","authors":"Yuan Yuan, Qi Gao, Hui Yang","doi":"10.1186/s12876-025-03985-x","DOIUrl":"10.1186/s12876-025-03985-x","url":null,"abstract":"<p><strong>Background: </strong>Rectal resection could potentially cause low anterior resection syndrome (LARS). Although recent studies have reported the efficacy of enema against LARS, no systematic review and meta-analysis has been conducted.</p><p><strong>Methods: </strong>A systematic search was conducted in PubMed, EMBASE, MEDLINE, CINAHL Complete, Cochrane library and Web of Science. Eligible studies that quantified the effect of enema vs. other approaches on LARS following rectal resection were selected. Meta-analysis was conducted by using RevMan 5.4 software and StataMP 17. Where meta-analysis was not possible, vote counting was performed.</p><p><strong>Results: </strong>This study comprised five RCTs with 159 participants and meta-analysis was performed in 4 studies. Compared with the control group, enema reduced LARS score with mean differences of -10.84 (95% CI: -16.71 to -4.98, P = 0.0003). Subgroup analysis based on the type of enema were performed, with three European studies using retrograde enema and one Asian study using antegrade enema, with mean differences of -13.77 (95% CI: -17.97 to -9.57, P < 0.00001) and -4.86 (95% CI: -9.26 to -0.46, P = 0.03), respectively. According to follow-up period, two trials reported short-term effects and the other two investigated medium/long-term effects with mean differences of -14.22 (95% CI: -20.05 to -8.38, P = 0.23) and -7.59 (95% CI: -14.47 to -0.71, P = 0.13), respectively. One study that used antegrade enema was key contributor to the substantial interstudy heterogeneity by the leave-one-out sensitivity analysis. After exclusion of this study, no heterogeneity was found (t² = 0.00; χ² = 1.63, df = 2, p = 0.44; I² = 0%). Vote counting also showed positive effects of enema on LARS.</p><p><strong>Conclusions: </strong>Enema, particularly retrograde enema, is effective in managing LARS. However, the effectiveness of antegrade enema deserves further investigation. The short-term effects of enema are more pronounced compared to long-term outcomes. Due to the limited number of included studies, these findings should be taken cautiously. More RCTs on other continents are needed to validate the impact of enema on LARS, as well as to develop standardised protocols to facilitate clinical practice.</p><p><strong>Prospero registration: </strong>CRD42024539973.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"401"},"PeriodicalIF":2.5,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12102822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of post-market adverse events of lubiprostone: a real-world adverse event analysis from the FAERS database.","authors":"Qingqing Li, Jijun Zhang, Chuanli Yang, Xiushan Dong, Yan Wang","doi":"10.1186/s12876-025-03987-9","DOIUrl":"10.1186/s12876-025-03987-9","url":null,"abstract":"<p><strong>Objective: </strong>Lubiprostone is a selective intestinal chloride channel activator approved for treating chronic idiopathic constipation and constipation-predominant irritable bowel syndrome in adults. However, real-world data on its long-term safety, particularly regarding adverse events necessitating ongoing supplementation, remain limited.</p><p><strong>Methods: </strong>Data from the FDA Adverse Event Reporting System (FAERS) database were collected from the second quarter of 2006 to the fourth quarter of 2023. The data was normalized, and various signal quantification techniques such as Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS) were used for analysis.</p><p><strong>Results: </strong>A total of 1436 adverse event reports associated with lubiprostone were extracted from the FAERS database. These reports indicated a higher proportion of female patients compared to male patients (65.39% vs. 21.10%). Among those with explicit age data, the largest proportion of patients were 45-65 years old (20.6% of reports), followed by those ≥ 75 (19.9%), 18-45 (14.8%), and 65-75 years (10.1%). Adverse events induced by lubiprostone were observed in 24 System Organ Classes (SOCs), including common gastrointestinal disorders, general disorders, administration site conditions, as well as respiratory, thoracic, and mediastinal disorders, consistent with findings from clinical trials. Applying four algorithms simultaneously, 22 SOC_S were detected, revealing a total of 57 positive response items, including 22 related to the digestive system. The most stringent algorithm, empirical Bayesian geometric mean (EBGM), highlighted severe gastrointestinal adverse reactions like gastric fistula (n = 5, ROR = 150.03, PRR = 149.87, IC = 7.21, EBGM = 147.71) and ischemic colitis (n = 19, ROR = 36.78, PRR = 36.63, IC = 5.19, EBGM = 36.51), which were not listed in the drug insert. This suggests the need for heightened vigilance towards these potential adverse reactions during clinical use.</p><p><strong>Conclusions: </strong>Our study comprehensively evaluated the safety of lubiprostone in the post-marketing setting. Despite its therapeutic advantages, there is a potential for various systemic adverse effects. In addition to adverse events consistent with information from existing clinical trials and the insert, we discovered several serious localized adverse reactions and previously unreported systemic adverse reactions. These may be potentially associated with lubiprostone, but are not confirmed adverse effects. This will provide valuable evidence for future studies and further prospective clinical trials to confirm these results and elucidate the relationship between them, thus better guiding the clinical practice of lubiprostone.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"395"},"PeriodicalIF":2.5,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12096535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ascites complications risk factors of decompensated cirrhosis patients: logistic regression and prediction model.","authors":"Xiaolong Zheng, Wei Wei","doi":"10.1186/s12876-025-04002-x","DOIUrl":"10.1186/s12876-025-04002-x","url":null,"abstract":"<p><strong>Objective: </strong>The study mainly aim at exploring the ascites risk factors among decompensated cirrhosis patients via constructing the prediction model of ascites incidence.</p><p><strong>Methods: </strong>Here, we recruited 148 decompensated cirrhosis patients for analysis, their laboratory tests and complications recorded. T-test, chi-square test, single-factor logistic regression, multi-factor logistic regression, and nomogram model were used to investigate the ascites occurred factors in decompensated cirrhosis patients with ascites. To validate the data analysis results, we applied the receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA) to evaluate the discrimination, calibration, and clinical usefulness of the prediction model, respectively.</p><p><strong>Results: </strong>Serum creatinine levels were higher in the cirrhotic ascites group than in the non-ascites group. The ascites group had lower albumin and serum sodium levels, as well as a lower incidence of variceal bleeding and varicose veins compared to the non-ascites group.</p><p><strong>Conclusion: </strong>Varicose veins, variceal bleeding, and serum sodium levels are significant factors contributing to ascites development in cirrhosis. Furthermore, decreased serum albumin and elevated creatinine levels are important indicators of poor prognosis. Nomograms can improve clinicians' informed decision-making for patients with decompensated cirrhosis, ultimately reducing ascites risk.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"397"},"PeriodicalIF":2.5,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges and needs in the management of non-alcoholic fatty liver disease from the perspective of gastroenterology and hepatology specialists: a qualitative study.","authors":"Farzad Salmanizadeh, Sakineh Sabzevari, Sara Shafieipour, Mohammad Javad Zahedi, Afshin Sarafinejad","doi":"10.1186/s12876-025-03921-z","DOIUrl":"10.1186/s12876-025-03921-z","url":null,"abstract":"<p><strong>Background: </strong>Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, and it poses a significant threat to public health. There is insufficient documented evidence about the problems and needs of patients and physicians in managing NAFLD. This study aimed to explore the challenges and needs in managing NAFLD from the perspective of gastroenterology and hepatology (GH) specialists.</p><p><strong>Methods: </strong>This qualitative study was conducted from January to September 2023. Fifteen Iranian GH specialists selected by purposive sampling. Data were collected through semi-structured interviews. The interviews were analyzed inductively using the Elo and Kyngas content analysis approach. The criteria proposed by Guba and Lincoln were used to ensure the study's validity.</p><p><strong>Results: </strong>The identified challenges were divided into thirteen main categories (34 subcategories and 117 primary codes), and the identified needs were divided into eight main categories (21 subcategories and 97 primary codes). The main categories of the challenges were chronic nature and time-consuming differential diagnosis, complex treatment process, defects in the patient management process, shortcomings of the healthcare system, the effect of unhealthy eating and cultural and social factors on the diet, incorrect attitude of patients, lack of knowledge and awareness of patients, lack of comprehensive treatment plans based on patients' conditions, defect in knowledge and awareness of physicians, inadequate cooperation of patients, defects in the process of recording and monitoring information and providing feedback, insufficient policies and plans in the prevention of NAFLD, and economic problems. The main categories of needs included developing a comprehensive treatment plan, updating physicians' knowledge and creating standard treatment protocols, changing attitudes and empowering patients, informing and educating patients, establishing multi-specialty clinics for NAFLD treatment, establishing peer support groups and facilitating communication, utilizing digital technology to track patient information and monitor their progress, and supportive, educational, prevention, and management policies in the treatment of NAFLD.</p><p><strong>Conclusions: </strong>This study showed that managing NAFLD involves physical, psychological, nutritional, sports, economic, and social aspects and requires multidisciplinary clinical approaches, digital technologies, and supportive and educational policies. These findings have important implications that can help patients, physicians, and policymakers design better lifestyle prescriptions to manage NAFLD.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"396"},"PeriodicalIF":2.5,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12096504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between inflammatory biomarkers and gallstones in Americans under 50 years old.","authors":"Shuqin Cheng, Yaping Zhang, Lu Jiang, Jiana Li, Runci Jiang, Fengmei Wang","doi":"10.1186/s12876-025-03994-w","DOIUrl":"10.1186/s12876-025-03994-w","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to assess the link between inflammatory biomarkers (like the neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammatory index (SII), and systemic inflammation response index (SIRI)) and gallstones in American individuals aged under 50 years.</p><p><strong>Methods: </strong>This study utilized data from the National Health and Nutrition Examination Survey (NHANES) covering 2017 to 2020, centering on individuals under 50 years with comprehensive data on NLR, SII, SIRI, and gallstones. It employed a weighted multiple logistic regression approach to investigate the link between inflammatory biomarkers and gallstones. Furthermore, dose-response relationships and threshold effects were evaluated utilizing restricted cubic spline (RCS) methods and segmented linear regression models. Subgroup examinations and interaction assessments were conducted, too.</p><p><strong>Results: </strong>The investigation encompassed a total of 3,295 individuals. Upon comprehensive adjustment for variables, multivariate logistic regression revealed a positive relationship between inflammatory biomarkers and gallstones: ln-NLR (OR = 1.68, 95% CI: 1.06-2.66, p = 0.033), ln-SII (OR = 1.79, 95% CI: 1.08-2.98, p = 0.032), and ln-SIRI (OR = 1.46, 95% CI: 1.07-1.99, p = 0.025). A non-linear association, shaped like an inverse \"U\", was noted between ln-SIRI and gallstones. To the left of the inflection point (ln-SIRI = 0.35, SIRI = 1.42), a positive link existed between ln-SIRI and gallstones (OR = 2.45, 95% CI: 1.20-5.03); whereas, to the right of the inflection point, the association was statistically insignificant (OR = 0.60, 95% CI: 0.21-1.73).</p><p><strong>Conclusion: </strong>ln-NLR and ln-SII exhibited a linear and positive relationship with the likelihood of developing gallstones. ln-SIRI demonstrated a nonlinear dose-response relationship with gallstone risk, characterized by an inverted \"U\" shape.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"393"},"PeriodicalIF":2.5,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12096754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between proteinuria changes and colorectal cancer incidence: evidence from a nationwide cohort study.","authors":"Soo Young Oh, Kyung-Do Han, Ga Yoon Ku, Won-Kyung Kang","doi":"10.1186/s12876-025-03935-7","DOIUrl":"10.1186/s12876-025-03935-7","url":null,"abstract":"<p><strong>Background: </strong>The presence of excess proteins in the urine, known as proteinuria, has been linked to various health conditions, including chronic kidney disease and cancer. Emerging evidence suggests an association between proteinuria and colorectal cancer, a leading global cause of cancer-related morbidity and mortality. However, the impact of changes in proteinuria status on colorectal cancer risk remains unclear. Understanding this relationship may identify proteinuria as a modifiable risk factor for colorectal cancer prevention.</p><p><strong>Methods: </strong>This retrospective cohort study analyzed data from 3,043,138 adults aged over 19 years who participated in biennial health screenings by the South Korean National Health Insurance Service in 2010 and 2012. Participants were classified into four groups based on changes in proteinuria status: no proteinuria, newly developed proteinuria, recovered proteinuria, and persistent proteinuria. Proteinuria was measured using dipstick urinalysis, and colorectal cancer diagnoses were identified using medical records. Cox proportional hazards models adjusted for age, sex, body mass index, lifestyle behaviors, and other confounders were used to estimate cancer risk.</p><p><strong>Results: </strong>Over a median follow-up period of 9.19 years, 36,846 participants (1.2%) developed colorectal cancer. After adjusting for multiple confounding factors, including age, sex, lifestyle behaviors, medication use, diabetes, hypertension, dyslipidemia, and chronic kidney disease, the persistent proteinuria group demonstrated a significantly higher risk of colorectal cancer compared with the proteinuria-free group (adjusted hazard ratio [aHR], 1.27; 95% CI, 1.13-1.42). Additionally, greater severity of proteinuria was associated with progressively increased colorectal cancer risk (aHR for overt proteinuria [+ 2 to + 4], 1.17; 95% CI, 1.05-1.29).</p><p><strong>Conclusions: </strong>Changes in proteinuria status are significantly associated with colorectal cancer risk. Persistent proteinuria poses the highest risk, while transient proteinuria also elevates risk compared to individuals without proteinuria. Regular monitoring and management of proteinuria could potentially be beneficial in identifying individuals at higher colorectal cancer risk, suggesting its possible role as an indicator for targeted prevention strategies. However, further research, including randomized controlled trials, is necessary to confirm any causal relationship.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"392"},"PeriodicalIF":2.5,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between circadian syndrome and MASLD risk: evidence from a large cross-sectional study.","authors":"Jihan Sun, Shuqi Mao, Caide Lu","doi":"10.1186/s12876-025-03997-7","DOIUrl":"10.1186/s12876-025-03997-7","url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic liver condition closely associated with metabolic syndrome and linked to circadian disruptions. Circadian Syndrome (CircS), a constellation of metabolic and circadian dysregulations, has emerged as a risk factor for metabolic disorders. This study aims to examine the association between CircS and MASLD and to evaluate the potential relevance of CircS in identifying individuals at elevated MASLD risk.</p><p><strong>Methods: </strong>Data from 2,288 participants in the 2017-2018 U.S. National Health and Nutrition Examination Survey (NHANES) cycle were analyzed. Weighted logistic regression models were used to assess the overall association between CircS and MASLD. Restricted cubic spline (RCS) analyses were applied to evaluate the dose-response relationship. Subgroup analyses were conducted to explore potential effect modifiers underlying the CircS-MASLD association.</p><p><strong>Results: </strong>A significant association between CircS and MASLD was observed. Application of weighted logistic regression revealed that individuals with CircS had increased odds of MASLD (adjusted OR = 4.123, 95% CI: 2.489-6.832, P = 0.001) after adjusting for demographic, lifestyle, and metabolic covariates. The association was consistent across demographic subgroups, with a linear trend showing higher CircS scores correlating with increased MASLD risk.</p><p><strong>Conclusion: </strong>CircS is significantly associated with MASLD and may have potential implications for early risk identification and targeted intervention. However, its clinical utility requires further validation in prospective studies before integration into routine practice.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"391"},"PeriodicalIF":2.5,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial development and validation of a disease-specific resilience measure for inflammatory bowel disease: the RISE-IBD instrument.","authors":"Michelle Mendiolaza, Camila Vicioso, Wamia Siddiqui, Karan Lingineni, Ksenia Gorbenko, Parul Agarwal, Laurie Keefer","doi":"10.1186/s12876-025-03971-3","DOIUrl":"10.1186/s12876-025-03971-3","url":null,"abstract":"<p><strong>Background: </strong>Inflammatory bowel diseases (IBDs) have a substantial effect on the well-being and quality of life of patients. While resilience may help alleviate psychological and physical burdens in individuals with IBD, there is no disease-specific measure that currently exists to accurately quantify this construct in the context of IBD. This study aimed to psychometrically validate the new Resilience Scale for IBD (RISE-IBD).</p><p><strong>Methods: </strong>A preliminary scale was developed including 17 items generated from a qualitative study that centered on patient focus group discussions, conversations with IBD healthcare providers, and evaluation of two validated resilience measures. In this cross-sectional study, the scale's reliability, validity, and consistency were assessed in a sample of 91 patients with IBD.</p><p><strong>Results: </strong>The 17-item RISE-IBD was reduced to a 14-item measure. The revised RISE-IBD, comprising four resilience domains (Disease Acceptance, Self-Reliance, Flexibility, Persistence), demonstrated strong internal consistency (Cronbach's α = 0.82) and excellent re-test reliability (r = 0.91). The scale exhibited significantly positive correlations with the Connor-Davidson Resilience Scale (r = 0.74) and Brief Resilience Scale (r = 0.59), as well as with a disease-specific quality of life scale, the IBD Questionnaire (τ = 0.33). It also showed significantly negative associations with psychological distress measured by the Brief Symptom Inventory (τ = -0.36) and IBD-related disability assessed by the IBD Disability Index (τ = -0.30).</p><p><strong>Conclusions: </strong>The RISE-IBD demonstrates its strong potential as a psychometrically reliable tool for assessing resilience in patients with IBD. By evaluating resilience across multiple domains, healthcare providers can gain a thorough understanding of patients' coping mechanisms and tailor interventions accordingly. Future research should focus on further strengthening the scale's psychometric properties by validating its use across diverse gastrointestinal patient populations and exploring the relationship between resilience and key IBD outcomes.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"390"},"PeriodicalIF":2.5,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of chitosan nanoparticles conjugated with the cell free supernatant of Bifidobacterium bifidum on the expression of genes related to colorectal cancer in colon adenocarcinoma (Caco-2) cell line.","authors":"Rahimeh Maqsoodi, Masoumeh Saberpour, Bita Bakhshi, Fatemeh Fallah","doi":"10.1186/s12876-025-03923-x","DOIUrl":"10.1186/s12876-025-03923-x","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is emerged as a global problem with high mortality rate; hence, finding of alternative treatment approaches is essential. The purposes of this research are to assess the impact of chitosan nanoparticles conjugated with the cell free supernatant of Bifidobacterium bifidum (CTNP/B.b-sup) on genes associated with CRC signaling pathways.</p><p><strong>Methods: </strong>The novel nano-drug were fabricated via an ionic gelation technique and analyzed using transmission electron microscopy (TEM) and dynamic light scattering (DLS) methods. The release of protein and entrapment efficiency (EE) of CTNP/B.b-sup were assessed using a BCA protein assay. Following an investigation into the toxicity of CTNP/B.b-sup on Caco-2 cells by MTT assay, the expression of genes associated with CRC signaling pathways was evaluated utilizing real-time PCR method.</p><p><strong>Results: </strong>CTNP/B.b-sup exhibited a suitable morphology with a particle size of 453.1 ± 230.8 nm and zeta potential of 9.11 ± 3.6 mV. The protein released was 75.5% at pH ~ 6.8 within 48 h with 83.3% of EE. The viability of Caco-2 cells against CTNP/B.b-sup was 90.3%. The effects of CTNP/B.b-sup on the expression levels of various oncogenes reveal a significant decrease in the expression of β-Catenin, PI3K, TGF-α, Bcl2, TLR4, CEA, and TGF-β oncogenes by 0.96, 0.37, 0.03, 0.41, 0.88, 0.69, and 0.71-fold, respectively. CTNP/B.b-sup induced the most significant reduction in TGF-α oncogene expression, with a decrease of 0.03-fold. Conversely, the strongest induction was observed in the expression of Caspase9 suppressor, with a 73.4-fold increase.</p><p><strong>Conclusion: </strong>In the present study, the CTNP/B.b-sup was demonstrated to possess the capability of modulating genes associated with CRC progression, thereby highlighting its significant pro-apoptotic potential. It can be concluded that CTNP/B.b-sup is a suitable drug delivery system with anticancer properties, which can be regarded as a complementary therapeutic approach for the treatment of CRC.</p>","PeriodicalId":9129,"journal":{"name":"BMC Gastroenterology","volume":"25 1","pages":"394"},"PeriodicalIF":2.5,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12096731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}